SUFU was detected with lower expression levels in higher FIGO (International Federation of Gynaecology and Obstetrics) stages compared to lower stages [42], as the authors confirmed that the HH signaling pathway was active in ovarian tumors and that GLI1 and SUFU were associated with the tumor type and FIGO stage. This evidence concerns the gene SUFU and ovarian neoplasm.